LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! Apparently, research never fully takes a break. While most of the major news will come in the fall, we still have some interesting results this week. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. For more details on everything I talk about here, you can always visit ProstateWarriors.com.​

Clinical Research

• Phase 3: Pluvicto (177Lu-PSMA-617) Shows Promise in mHSPC
  ​The PSMAddition Phase 3 trial met its primary endpoint in June, showing that Pluvicto, added to ADT and androgen receptor pathway inhibitors, significantly extends radiographic progression-free survival (rPFS) in mHSPC. Though overall survival (OS) data are still maturing, early trends are positive. Safety remains consistent with earlier studies. Full results are expected in the fall (at ESMO 2025probably), with regulatory submissions planned for late 2025.
  ​
• Triplet Therapy Offers Best Survival for mHSPC with Visceral Metastases
  ​A new systematic review and network meta-analysis of eight phase 3 trials shows that triplet therapy—androgen deprivation therapy (ADT) + docetaxel + darolutamide—offers the strongest overall survival benefit for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and visceral disease, reducing death risk by 58%. Though limited by lack of individual patient data and visceral site breakdown, the analysis clearly favors triplet therapy. When not feasible, ADT with either docetaxel or abiraterone is preferred over other ARPI-based options.
  ​

Preclinical Research

• Exercise + Gut Microbes Enhance Immunotherapy via Formate​
  Exercise boosts CD8 T cell–mediated antitumor immunity, improving the effectiveness of immune checkpoint inhibitors (ICIs),but only when gut microbes are present. Researchers identified formate, a metabolite from microbial one-carbon metabolism, as the key mediator. Formate supplementation alone reproduced many benefits of exercise in mice and enhanced anti-PD-L1 therapy. Human data also link higher formate and pfl enzyme levels to better anti-PD-1 responses.
  ​
• In Situ CAR-T Cell Generation: A Game Changer?
  ​A breakthrough preclinical study shows that mRNA-loaded lipid nanoparticles (LNPs) can generate CAR-T cells directly in the body, successfully treating B-cell lymphoma in mice with minimal toxicity. The technique could be adapted for solid tumors, including prostate cancer, by targeting PSMA and enabling repeat dosing or multi-target strategies. This approach may greatly lower treatment costs and broaden access.
  ​
• CRISPR Uncovers Key Vitamin D Gene for Cancer Therapy
  ​Using CRISPR, researchers identified SDR42E1 as essential for converting vitamin D into calcitriol. Disabling it in colorectal cancer cells led to a 53% drop in viability and disrupted cancer-related genes, making SDR42E1 a potential target for selective, low-toxicity therapies. While promising, further research is needed due to vitamin D’s complex biological roles.
  ​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max